Related posts

TSX and Dow gain for the weekcash, credit and health3 Best U.S. Healthcare ETFs
Investor Insights

This summary was created by AI, based on 16 opinions in the last 12 months.

Experts are generally positive about Thermo Fisher Scientific. They believe the company is well-positioned for growth, especially in the healthcare industry. Despite some short-term challenges, the long-term outlook for TMO-N appears to be promising. The company's strong track record in acquisitions and recurring revenue model are seen as key strengths. Overall, the experts are bullish on Thermo Fisher Scientific's prospects for the future.

Fair Value

Last week, they reported strong earnings and an in-line full-year forecast, but stocks fell nearly 5%. That was a sell-the-news reaction, he thinks. Management said that 2023 was their transition year when they unwound excess inventory and 2024 is their recovery year, particularly in the second half. Buy it now. Macro trends: he thinks we're starting a huge innovation cycle in pharma in weight-loss drugs among others, all helped by generative AI. Biopharma is entering a red-hot period after years of pain.

electrical / electronic

He bought this in mid-2023 on a dip. It's been consolidating the healthcare space for the last 10 years. Are #1 in this space. He expects sales and their PE to improve.

electrical / electronic

She bought in summer, stock's not done too much, so it gets to be a Top Pick again. Vast array of picks and shovels to the healthcare industry. Reduced guidance a couple of times, very unusual for them: weakness in China, general caution in spending, and Covid-double-ordered inventory destocking. Likes long-term fundamentals of healthcare industry, and TMO will participate. Yield is 0.3%.

(Analysts’ price target is $536.48)
electrical / electronic

Is up 11% in the past month. Their customers have finished clearing out their excess inventory after a year. Better US-China relations means more sales for TMO.

electrical / electronic

TMO is a leader in life sciences and diagnostics. He recently added. The entire sector has some over-supply. This is the bottom of the cycle. Lower risk, less upside, more diversified. Historically, good at acquisitions. Good long-term hold, but right now it's all about waiting for funding to come back to the sector.

When the cycle turns, both will do well and will probably outperform.

electrical / electronic

It is the leading global player in life sciences and tools. It provides drug companies, pharmaceuticals and labs and in fact is vital to the pharmaceutical industry in helping with drug development. The overhang is weakness in China and bio-tech companies but this should be a temporary headwind. With a good management team it is growing in the U.S. with several acquisitions. The pull back makes it a good time to buy for the long term.       Buy 21  Hold 6  Sell 1

(Analysts’ price target is $592.27)
electrical / electronic

Spend the last ~20 years consolidating scientific/diagnostics tools market.
Very strong demand for health care products.
Strong pipeline of R&D.
Expecting a 5-7% revenue growth & double digit earnings growth.
Great compounding business for long term shareholder.

electrical / electronic

Leader in technology in sectors that are solid but not hot. Largest player in devices needed for research. Successfully integrates acquisitions. Pick and shovels. Revenue growth of 8-10%. Not cheap, but foresees 10-15% growth per annum for 5-6 years. Yield is 0.26%.

(Analysts’ price target is $617.21)
electrical / electronic

Healthcare products and services. Benefitted from Covid, and financial windfall can be used to reinvest in the business. Growth will be flat this year and then pick up. Raised growth target to 7-9% annually on topline. 82% of revenue is recurring, a defensive characteristic. Yield is 0.26%. 

(Analysts’ price target is $619.33)
electrical / electronic

Leading health care providers to pharma companies.
Excellent at M&A the past 10 years.
Large R&D pipeline.
Also good in hardware sales for new drugs.
Benefited from Covid-19 pandemic.
Recent share price weakness presenting good buying opportunity.
Expecting growth of revenue and earnings. 

electrical / electronic

Recently bought this. TMO benefitted during Covid because companies used their products and services. Shares are off 22% from highs. Grows organically and from M&A. They generate cash flow and earnings, which will be down this year. But they invest in companies and R&D well. Pays a small dividend though.

(Analysts’ price target is $623.56)
electrical / electronic

October-November marked a major low. Range-bound between $600-520. As long as it doesn't take out the $520 level to the downside, doesn't mind nibbling here for the longer term. He expects we're starting a new 4-year cycle for a 3-5 year bull market. See his Top Picks.

electrical / electronic

It has differing moving parts and has a growth component - lab samples go to their products associated with lab work. Personalized medicine is a major growth area and means more specific types of testing. This will benefit TMO

electrical / electronic

Great company over the long term.
Weak share price a good time to invest.
Grow company that has volatility.
M&A strategy will be good if assets remain cheap.

electrical / electronic

A great company, a mid-tech conglomerate that aggressively buys companies and boasts recurring revenues. We're approaching a recession, but buy for the long-term and buy in tranches.

electrical / electronic
Showing 1 to 15 of 78 entries

Thermo Fisher Scientific(TMO-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 10

Stockchase rating for Thermo Fisher Scientific is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Thermo Fisher Scientific(TMO-N) Frequently Asked Questions

What is Thermo Fisher Scientific stock symbol?

Thermo Fisher Scientific is a American stock, trading under the symbol TMO-N on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO-N

Is Thermo Fisher Scientific a buy or a sell?

In the last year, 10 stock analysts published opinions about TMO-N. 10 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Thermo Fisher Scientific.

Is Thermo Fisher Scientific a good investment or a top pick?

Thermo Fisher Scientific was recommended as a Top Pick by on . Read the latest stock experts ratings for Thermo Fisher Scientific.

Why is Thermo Fisher Scientific stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Thermo Fisher Scientific worth watching?

10 stock analysts on Stockchase covered Thermo Fisher Scientific In the last year. It is a trending stock that is worth watching.

What is Thermo Fisher Scientific stock price?

On 2024-02-28, Thermo Fisher Scientific (TMO-N) stock closed at a price of $568.95.